Atea Pharmaceuticals Stock Analysis
AVIR Stock | USD 3.14 0.05 1.62% |
Atea Pharmaceuticals is undervalued with Real Value of 4.09 and Target Price of 7.4. The main objective of Atea Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Atea Pharmaceuticals is worth, separate from its market price. There are two main types of Atea Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Atea Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Atea Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Atea Stock trading window is adjusted to America/New York timezone.
Atea |
Atea Stock Analysis Notes
About 69.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea Pharmaceuticals recorded a loss per share of 2.07. The entity last dividend was issued on the 9th of November 2012. The firm had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people. For more info on Atea Pharmaceuticals please contact the company at 857 284 8891 or go to https://ateapharma.com.Atea Pharmaceuticals Investment Alerts
Atea Pharmaceuticals generated a negative expected return over the last 90 days | |
Net Loss for the year was (135.96 M) with loss before overhead, payroll, taxes, and interest of (78.28 M). | |
Atea Pharmaceuticals currently holds about 684.48 M in cash with (85.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Atea Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from MacroaxisInsider: Insider Trading |
Atea Pharmaceuticals Upcoming and Recent Events
27th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Atea Largest EPS Surprises
Earnings surprises can significantly impact Atea Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-08-12 | 2021-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2023-05-08 | 2023-03-31 | -0.48 | -0.43 | 0.05 | 10 | ||
2022-05-10 | 2022-03-31 | -0.58 | -0.51 | 0.07 | 12 |
Atea Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Atea Pharmaceuticals' ESG score is a quantitative measure that evaluates Atea Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Atea Pharmaceuticals' operations that may have significant financial implications and affect Atea Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Atea Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Almitas Capital Llc | 2024-12-31 | 752 K | Northern Trust Corp | 2024-12-31 | 704.9 K | Charles Schwab Investment Management Inc | 2024-12-31 | 659.5 K | Citadel Advisors Llc | 2024-09-30 | 595.2 K | Newtyn Management Llc | 2024-12-31 | 580 K | Federated Hermes Inc | 2024-09-30 | 572.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 567 K | Two Sigma Advisers, Llc | 2024-12-31 | 493.6 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 390.9 K | Blackrock Inc | 2024-12-31 | 9.1 M | Bml Capital Management Llc | 2024-12-31 | 7.6 M |
Atea Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 265.21 M.Atea Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.22) | |
Return On Capital Employed | (0.26) | (0.28) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | (0.28) | (0.27) |
Management Efficiency
Atea Pharmaceuticals has return on total asset (ROA) of (0.1425) % which means that it has lost $0.1425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3346) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals' management efficiency ratios could be used to measure how well Atea Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Atea Pharmaceuticals' Non Current Assets Total are relatively stable compared to the past year. As of 02/26/2025, Non Currrent Assets Other is likely to grow to about 1.7 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.99 | 3.76 | |
Tangible Book Value Per Share | 5.99 | 3.76 | |
Enterprise Value Over EBITDA | (0.85) | (0.89) | |
Price Book Value Ratio | 0.41 | 0.43 | |
Enterprise Value Multiple | (0.85) | (0.89) | |
Price Fair Value | 0.41 | 0.43 | |
Enterprise Value | 129.9 M | 123.4 M |
The operational strategies employed by Atea Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 26th of February, Atea Pharmaceuticals shows the risk adjusted performance of 0.0073, and Mean Deviation of 2.03. Atea Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atea Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Atea Pharmaceuticals is priced correctly, providing market reflects its regular price of 3.14 per share. Given that Atea Pharmaceuticals has information ratio of (0.01), we suggest you to validate Atea Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Atea Pharmaceuticals Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Atea Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Atea Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Atea Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atea Pharmaceuticals Outstanding Bonds
Atea Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atea Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atea bonds can be classified according to their maturity, which is the date when Atea Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ATH 255 19 NOV 30 Corp BondUS04686E2U56 | View | |
ATH 25 24 MAR 28 Corp BondUS04686E2Y78 | View | |
ATH 345 15 MAY 52 Corp BondUS04686JAE10 | View | |
ATH 395 25 MAY 51 Corp BondUS04686JAD37 | View | |
US04686JAC53 Corp BondUS04686JAC53 | View | |
ATHENE HLDG LTD Corp BondUS04686JAA97 | View | |
ATHENE HLDG LTD Corp BondUS04686JAB70 | View | |
ATH 665 01 FEB 33 Corp BondUS04686JAF84 | View |
Atea Pharmaceuticals Predictive Daily Indicators
Atea Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atea Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Atea Pharmaceuticals Corporate Filings
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
16th of December 2024 Other Reports | ViewVerify | |
F4 | 12th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Atea Pharmaceuticals Forecast Models
Atea Pharmaceuticals' time-series forecasting models are one of many Atea Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atea Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Atea Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Atea Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atea shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Atea Pharmaceuticals. By using and applying Atea Stock analysis, traders can create a robust methodology for identifying Atea entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.35 | 0.37 | |
Operating Profit Margin | 0.35 | 0.37 | |
Net Profit Margin | 0.31 | 0.33 | |
Gross Profit Margin | 0.90 | 0.80 |
Current Atea Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atea analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atea analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
7.4 | Buy | 3 | Odds |
Most Atea analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atea stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atea Pharmaceuticals, talking to its executives and customers, or listening to Atea conference calls.
Atea Stock Analysis Indicators
Atea Pharmaceuticals stock analysis indicators help investors evaluate how Atea Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atea Pharmaceuticals shares will generate the highest return on investment. By understating and applying Atea Pharmaceuticals stock analysis, traders can identify Atea Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 188.7 M | |
Common Stock Shares Outstanding | 83.4 M | |
Total Stockholder Equity | 555.2 M | |
Tax Provision | 1 M | |
Quarterly Earnings Growth Y O Y | 2.641 | |
Property Plant And Equipment Net | 3.1 M | |
Cash And Short Term Investments | 578.1 M | |
Cash | 143.8 M | |
Accounts Payable | 4.3 M | |
Net Debt | -141.4 M | |
50 Day M A | 3.1592 | |
Total Current Liabilities | 32.4 M | |
Other Operating Expenses | 164.2 M | |
Non Current Assets Total | 4.5 M | |
Non Currrent Assets Other | 1.4 M | |
Stock Based Compensation | 49.4 M |
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.